PriceTargets.com logo

Janux Therapeutics - JANX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $49.75
  • Forecasted Upside: 246.93%
  • Number of Analysts: 15
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$14.34 As of 05/1/2026 05:00 PM ET
▼ -0.03 (-0.21%)

This chart shows the closing price for JANX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Janux Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JANX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JANX

Analyst Price Target is $49.75
▲ +246.93% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Janux Therapeutics in the last 3 months. The average price target is $49.75, with a high forecast of $100.00 and a low forecast of $14.00. The average price target represents a 246.93% upside from the last price of $14.34.

This chart shows the closing price for JANX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 polled investment analysts is to moderate buy stock in Janux Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 1 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
4/2/2026
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
5/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/28/2026JonesTradingLower TargetBuy ➝ Buy$50.00 ➝ $28.00
4/22/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
4/20/2026BarclaysDowngradeOverweight ➝ Underweight$29.00 ➝ $14.00
4/15/2026UBS GroupDowngradeBuy ➝ Neutral$57.00 ➝ $15.00
2/27/2026Cantor FitzgeraldLower TargetOverweight ➝ Overweight$150.00 ➝ $100.00
2/27/2026GuggenheimLower TargetBuy ➝ Buy$72.00 ➝ $68.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/20/2026Clear StrDowngradeStrong-Buy ➝ Hold
1/16/2026Piper SandlerLower TargetOverweight ➝ Overweight$42.00 ➝ $30.00
12/17/2025BarclaysLower TargetOverweight ➝ Overweight$48.00 ➝ $29.00
12/2/2025UBS GroupReiterated RatingBuy ➝ Buy$57.00
12/2/2025Stifel NicolausLower TargetBuy ➝ Buy$46.00 ➝ $38.00
12/2/2025HC WainwrightLower TargetBuy ➝ Buy$70.00 ➝ $45.00
12/2/2025WedbushReiterated RatingOutperform$76.00 ➝ $45.00
12/2/2025Bank of AmericaLower TargetBuy ➝ Buy$58.00 ➝ $49.00
12/2/2025Cantor FitzgeraldLower TargetOverweight ➝ Overweight$200.00 ➝ $150.00
11/25/2025HC WainwrightReiterated RatingBuy ➝ Buy$70.00
11/18/2025Wolfe ResearchInitiated CoveragePeer Perform
11/7/2025WedbushReiterated RatingOutperform$76.00
11/7/2025BarclaysBoost TargetOverweight ➝ Overweight$47.00 ➝ $48.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/17/2025BarclaysInitiated CoverageOverweight$47.00
9/16/2025BarclaysInitiated CoverageOverweight$47.00
9/10/2025Truist FinancialInitiated CoverageBuy$100.00
9/10/2025Stifel NicolausReiterated RatingBuy$45.00
9/3/2025GuggenheimInitiated CoverageBuy$72.00
9/3/2025GuggenheimInitiated CoverageBuy$72.00
8/18/2025Piper SandlerInitiated CoverageOverweight$42.00
7/11/2025Raymond James FinancialInitiated CoverageOutperform$65.00
3/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
2/28/2025ScotiabankLower TargetSector Perform ➝ Sector Perform$62.00 ➝ $41.00
2/28/2025WedbushReiterated RatingOutperform$75.00 ➝ $76.00
1/10/2025William BlairReiterated RatingOutperform
12/27/2024Lifesci CapitalUpgradeStrong-Buy
12/11/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
12/4/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$42.00 ➝ $62.00
12/3/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$79.00 ➝ $91.00
12/3/2024Stifel NicolausBoost TargetBuy ➝ Buy$70.00 ➝ $115.00
12/3/2024William BlairReiterated RatingOutperform
12/3/2024BTIG ResearchBoost TargetBuy$82.00 ➝ $100.00
12/3/2024HC WainwrightBoost TargetBuy ➝ Buy$63.00 ➝ $70.00
11/22/2024Leerink PartnersUpgradeStrong-Buy
11/22/2024Leerink PartnersInitiated CoverageOutperform$79.00
11/14/2024William BlairReiterated RatingOutperform
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
11/7/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00
10/24/2024UBS GroupInitiated CoverageBuy$69.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00
9/6/2024Stifel NicolausInitiated CoverageBuy$70.00
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
8/9/2024ScotiabankLower TargetSector Perform ➝ Sector Perform$47.00 ➝ $42.00
8/8/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00
8/8/2024WedbushReiterated RatingOutperform ➝ Outperform$74.00 ➝ $74.00
5/30/2024ScotiabankInitiated CoverageSector Perform$47.00
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $63.00
5/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00
5/8/2024WedbushBoost TargetOutperform ➝ Outperform$53.00 ➝ $74.00
4/16/2024JonesTradingInitiated CoverageBuy$70.00
3/21/2024BTIG ResearchInitiated CoverageBuy$62.00
3/20/2024Cantor FitzgeraldInitiated CoverageOverweight$100.00
3/13/2024Bank of AmericaBoost TargetBuy ➝ Buy$24.00 ➝ $48.00
3/11/2024WedbushReiterated RatingOutperform$53.00
2/27/2024William BlairReiterated RatingOutperform
2/27/2024WedbushBoost TargetOutperform ➝ Outperform$24.00 ➝ $53.00
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00
8/10/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
7/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
7/18/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00
4/5/2023WedbushInitiated CoverageOutperform$24.00
3/17/2023Bank of AmericaLower Target$29.00 ➝ $26.00
3/13/2023HC WainwrightReiterated RatingBuy$35.00
11/14/2022William BlairInitiated CoverageOutperform
7/6/2021Bank of AmericaInitiated CoverageBuy$35.00
7/6/2021TD CowenInitiated CoverageOutperform
7/6/2021EvercoreInitiated CoverageOutperform$35.00
7/6/2021HC WainwrightInitiated CoverageBuy$35.00
(Data available from 5/3/2021 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/3/2026

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Janux Therapeutics logo
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $14.34
Low: $14.14
High: $14.56

50 Day Range

MA: $14.29
Low: $13.03
High: $15.87

52 Week Range

Now: $14.34
Low: $12.12
High: $35.34

Volume

655,198 shs

Average Volume

933,257 shs

Market Capitalization

$874.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Janux Therapeutics?

The following equities research analysts have issued research reports on Janux Therapeutics in the last year: Bank of America Corporation, Barclays PLC, Cantor Fitzgerald, Clear Str Llc, Guggenheim, HC Wainwright, JonesTrading, Piper Sandler, Raymond James Financial, Inc., Stifel Nicolaus, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for JANX.

What is the current price target for Janux Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Janux Therapeutics in the last year. Their average twelve-month price target is $49.75, suggesting a possible upside of 246.9%. Truist Financial Corporation has the highest price target set, predicting JANX will reach $100.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $14.00 for Janux Therapeutics in the next year.
View the latest price targets for JANX.

What is the current consensus analyst rating for Janux Therapeutics?

Janux Therapeutics currently has 2 sell ratings, 3 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JANX.

What other companies compete with Janux Therapeutics?

Other companies that are similar to Janux Therapeutics include Telix Pharmaceuticals, Oruka Therapeutics, NewAmsterdam Pharma, Edgewise Therapeutics and Catalyst Pharmaceuticals. Learn More about companies similar to Janux Therapeutics.

How do I contact Janux Therapeutics' investor relations team?

The company's listed phone number is 858-751-4493 and its investor relations email address is [email protected]. The official website for Janux Therapeutics is www.januxrx.com. Learn More about contacing Janux Therapeutics investor relations.